The Influence of Ezetimibe on Gallbladder Function

Withdrawn before enrolling · Not applicable · Has a placebo group

Conditions studied: Chronic Acalculous Cholecystitis

In brief

Ezetimibe is a drug which inhibits the absorption of both dietary and biliary cholesterol in the small intestine. Ezetimibe has been approved for use in humans to lower serum cholesterol. The primary aim of this study is to determine if ezetimibe normalizes resting and residual volume in patients with chronic acalculous cholecystitis.

Key facts

Study ID

NCT00634140

Run by

Indiana University

People needed

0

Starts

2009-08-01

Expected to finish

2009-08-01

Last updated by the study team

2015-03-30

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with typical biliary pain and ejection fraction <30% on a HIDA scan.
• Must be > 18 years of age.

You may not qualify if…

• Subjects with gallstones seen on HIDA.
• Subjects on statin medication
• Subjects with known allergies to ezetimibe.
• Subjects who are pregnant or breast-feeding.

Where it is running

• Indiana University Hospital — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.